No Data
Xiamen Kingdomway Group (002626.SZ): The vitamin company has gradually resumed work and production since April and is currently operating at full capacity.
Xiamen Kingdomway Group (002626.SZ) investor interaction platform revealed that the vitamins company has gradually resumed work and production since April and is currently in full production.
Xiamen Kingdomway Group (002626.SZ): received one invention patent certificate.
On August 5th, Gelunhui announced that Xiamen Kingdomway Group (002626.SZ) and its wholly-owned subsidiary Inner Mongolia Kingdomway Pharmaceutical Co., Ltd. recently received a patent certificate issued by the National Intellectual Property Office for a method of producing coenzyme Q10 through fermentation. This application provides a controlled fermentation production method for CoQ10. The method may include cultivating a microbial culture of bacteria by providing a carbon source and an oxygen source, thereby producing bacteria, carbon dioxide, and lactic acid containing CoQ10 in the microbial culture. At the same time, in each stage of production, the concentration of carbon dioxide and/or lactic acid is maintained.
Kingdomway to Set Up 5 Million Yuan Biology Products Joint Venture
Xiamen Kingdomway Group (002626.SZ) plans to establish a joint venture with GenScript Biotech Corporation to promote deep cooperation between both parties.
Xiamen Kingdomway Group (002626.SZ) announced that its wholly-owned subsidiary Inner Mongolia Kingdomway Pharmaceutical Co., Ltd. (referred to as Kingdomway...
Xiamen Kingdomway Group (002626.SZ) plans to establish a joint venture, Jin Yuan Biology, with Yuan Yi Biology.
On July 31st, Gelonhui reported that Xiamen Kingdomway Group (002626.SZ) announced that its wholly-owned subsidiary Inner Mongolia Kingdomway Pharmaceutical Co., Ltd. (referred to as Kingdomway Pharmaceutical or Party A) and Yuanyi (Tianjin) Biological Technology Co., Ltd. (referred to as Yuanyi Biology or Party B) have signed an investment agreement (the "Agreement") on July 31, 2024 after friendly negotiation to jointly invest and establish Jin Yuan biological technology (Inner Mongolia) Co., Ltd. (hereinafter referred to as Jin Yuan biology or joint venture) subject to the name approved by the market supervision and administration department. The cooperation products determined by both parties are astaxanthin products, as well as other synthetic biology products agreed by both parties.
Does The Market Have A Low Tolerance For Xiamen Kingdomway Group Company's (SZSE:002626) Mixed Fundamentals?
No Data
